News Stocks Asston Pharmaceuticals Limited Announces Resignation of Statutory Auditor M/s. Doshi Doshi & CoAsston Pharmaceuticals Limited Announces Resignation of Statutory Auditor M/s. Doshi Doshi & Co
Asston Pharmaceuticals Limited announced the resignation of statutory auditor M/s. Doshi Doshi & Co, effective January 28, 2026, due to the firm's preoccupation with other assignments. The company confirmed no material concerns were raised by the auditor and stated that the Audit Committee and Board will appoint new statutory auditors to fill the vacancy. The auditing firm had completed the limited review for the half year ended September 30, 2025, before tendering their resignation.
*this image is generated using AI for illustrative purposes only.
Asston Pharmaceuticals Limited has announced the resignation of its statutory auditor M/s. Doshi Doshi & Co, Chartered Accountants, through a regulatory filing with BSE Limited dated January 29, 2026. The auditing firm tendered their resignation with immediate effect from January 28, 2026, citing professional constraints as the primary reason.
Auditor Resignation Details
M/s. Doshi Doshi & Co, with registration number 153683W, expressed their inability to continue as statutory auditors through a formal resignation letter dated January 28, 2026. The firm was originally appointed under Section 139 of the Companies Act, 2013, for a five-year term commencing from September 30, 2024, with the term scheduled to expire at the conclusion of the Annual General Meeting in 2029.
| Parameter: | Details |
|---|---|
| Auditor Name: | M/s. Doshi Doshi & Co |
| Registration Number: | 153683W |
| Resignation Date: | January 28, 2026 |
| Original Appointment: | September 30, 2024 |
| Scheduled Term End: | AGM 2029 |
Reason for Resignation
The auditing firm cited preoccupation with other assignments as the primary reason for their resignation. In their resignation letter, Doshi Doshi & Co stated that due to their commitments with other clients, they were unable to devote adequate time to the audit of Asston Pharmaceuticals' affairs. To maintain professional objectivity and audit quality, the firm considered it appropriate to step down from their position.
Company's Response and Next Steps
Asston Pharmaceuticals confirmed that the resigning auditor raised no concerns regarding the company's management, and there were no material reasons beyond those stated for the resignation. Consequently, no deliberation by the Audit Committee was required, and no disclosure of the Audit Committee's view was deemed applicable.
The company stated that the Audit Committee and Board would consider the appointment of new statutory auditors in due course to fill the casual vacancy created by the resignation. The appointment process and timeline will be communicated through appropriate regulatory channels once finalized.
Completed Audit Work
Prior to their resignation, M/s. Doshi Doshi & Co completed the limited review of Asston Pharmaceuticals' financial results for the half year ended September 30, 2025. The auditing firm submitted their limited review report on November 14, 2025, ensuring that the company's recent financial reporting obligations were fulfilled before the transition.
Regulatory Compliance
The resignation has been disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. All required documentation, including detailed information as per SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, has been provided to the stock exchange. The resigning auditor will file the prescribed Form ADT-3 with the Registrar of Companies within the stipulated timeframe as required under the Companies Act, 2013.
Historical Stock Returns for Asston Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -5.75% | -4.47% | -3.33% | -33.28% | -35.01% | -35.01% |
15
